{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T23:30:34Z","timestamp":1777764634104,"version":"3.51.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T00:00:00Z","timestamp":1555372800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T00:00:00Z","timestamp":1555372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2019,8,15]]},"abstract":"<jats:title>Summary<\/jats:title>\n          <jats:p><jats:italic>Purpose<\/jats:italic> Brentuximab vedotin (BV) is an anti-CD30 antibody-drug conjugate used in the treatment of several types of lymphomas. Expression of the target antigen has also been reported on a variety of malignant tumors of nonlymphoid origin. This phase 2, open-label study evaluated the safety and antitumor activity of BV in patients with CD30-expressing nonlymphomatous malignancies. <jats:italic>Methods<\/jats:italic> Patients were dosed with 1.8 or 2.4\u00a0mg\/kg BV once every three weeks. Antitumor activity was assessed at Cycles 2, 4, and every 4\u00a0cycles thereafter. Patients with stable disease or better were eligible to continue treatment until disease progression, unacceptable toxicity, or study closure. <jats:italic>Results<\/jats:italic> Of the 2693 patients screened, 3.8% had solid tumors with CD30 expression and 63 eligible patients with solid tumors enrolled in this study. The most common CD30 positive solid tumors were testicular cancer and mesothelioma. Both subtypes had more than one patient with an objective response. The median duration of BV exposure was 6.1\u00a0weeks. The disease control rate, defined as achieving stable disease or better at any point during the study, was 55%. The objective response rate was 11%, with a median duration of response of 2.92\u00a0months. The most common adverse events reported were fatigue (57%), nausea (33%), and decreased appetite (32%). <jats:italic>Conclusion<\/jats:italic> The safety profile of BV in patients with solid tumors was similar to the known safety profile of BV. In solid tumors, BV had modest activity as a single agent, which was similar to other second-line treatments already available to patients.<\/jats:p>","DOI":"10.1007\/s10637-019-00768-6","type":"journal-article","created":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T07:02:49Z","timestamp":1555398169000},"page":"738-747","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["A phase 2, open-label study of brentuximab vedotin in patients with CD30-expressing solid tumors"],"prefix":"10.1007","volume":"37","author":[{"given":"Jeffrey P.","family":"Sharman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer J.","family":"Wheler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence","family":"Einhorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Afshin","family":"Dowlati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geoffrey I.","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Hilton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John M.","family":"Burke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanya","family":"Siddiqi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy","family":"Whiting","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shadia I.","family":"Jalal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,4,16]]},"reference":[{"issue":"9","key":"768_CR1","doi-asserted-by":"publisher","first-page":"e45244","DOI":"10.1371\/journal.pone.0045244","volume":"7","author":"SL Buchan","year":"2012","unstructured":"Buchan SL, Al-Shamkhani A (2012) Distinct motifs in the intracellular domain of human CD30 differentially activate canonical and alternative transcription factor NF-kappaB signaling. PLoS One 7(9):e45244. https:\/\/doi.org\/10.1371\/journal.pone.0045244","journal-title":"PLoS One"},{"issue":"8","key":"768_CR2","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1182\/blood.V83.8.2045.2045","volume":"83","author":"HJ Gruss","year":"1994","unstructured":"Gruss HJ, Boiani N, Williams DE, Armitage RJ, Smith CA, Goodwin RG (1994) Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines. Blood 83(8):2045\u20132056","journal-title":"Blood"},{"issue":"1","key":"768_CR3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood.V85.1.1.bloodjournal8511","volume":"85","author":"B Falini","year":"1995","unstructured":"Falini B, Pileri S, Pizzolo G, Durkop H, Flenghi L, Stirpe F, Martelli MF, Stein H (1995) CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood 85(1):1\u201314","journal-title":"Blood"},{"issue":"3","key":"768_CR4","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1007\/s11899-010-0053-y","volume":"5","author":"KV Foyil","year":"2010","unstructured":"Foyil KV, Bartlett NL (2010) Anti-CD30 antibodies for Hodgkin lymphoma. Curr Hematol Malig Rep 5(3):140\u2013147. https:\/\/doi.org\/10.1007\/s11899-010-0053-y","journal-title":"Curr Hematol Malig Rep"},{"issue":"15","key":"768_CR5","doi-asserted-by":"publisher","first-page":"10540","DOI":"10.1074\/jbc.M510026200","volume":"281","author":"MS Sutherland","year":"2006","unstructured":"Sutherland MS, Sanderson RJ, Gordon KA, Andreyka J, Cerveny CG, Yu C, Lewis TS, Meyer DL, Zabinski RF, Doronina SO, Senter PD, Law C-L, Wahl AF (2006) Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates. J Biol Chem 281(15):10540\u201310547. https:\/\/doi.org\/10.1074\/jbc.M510026200","journal-title":"J Biol Chem"},{"issue":"13","key":"768_CR6","doi-asserted-by":"publisher","first-page":"4370","DOI":"10.1182\/blood-2007-06-097014","volume":"110","author":"E Oflazoglu","year":"2007","unstructured":"Oflazoglu E, Stone IJ, Gordon KA, Grewal IS, van Rooijen N, Law C-L, Gerber HP (2007) Macrophages contribute to the antitumor activity of the anti-CD30 antibody SGN-30. Blood 110(13):4370\u20134372. https:\/\/doi.org\/10.1182\/blood-2007-06-097014","journal-title":"Blood"},{"issue":"32","key":"768_CR7","doi-asserted-by":"publisher","first-page":"3750","DOI":"10.1200\/JCO.2014.60.3969","volume":"33","author":"YH Kim","year":"2015","unstructured":"Kim YH, Tavallaee M, Sundram U, Salva KA, Wood GS, Li S, Rozati S, Nagpal S, Krathen M, Reddy S, Hoppe RT, Nguyen-Lin A, Weng WK, Armstrong R, Pulitzer M, Advani RH, Horwitz SM (2015) Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and Sezary syndrome with variable CD30 expression level: a multi-institution collaborative project. J Clin Oncol 33(32):3750\u20133758. https:\/\/doi.org\/10.1200\/JCO.2014.60.3969","journal-title":"J Clin Oncol"},{"issue":"8","key":"768_CR8","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1158\/2326-6066.CIR-13-0198","volume":"2","author":"P Muller","year":"2014","unstructured":"Muller P, Martin K, Theurich S, Schreiner J, Savic S, Terszowski G, Lardinois D, Heinzelmann-Schwarz VA, Schlaak M, Kvasnicka HM, Spagnoli G, Dirnhofer S, Speiser DE, von Bergwelt-Baildon M, Zippelius A (2014) Microtubule-depolymerizing agents used in antibody-drug conjugates induce antitumor immunity by stimulation of dendritic cells. Cancer Immunol Res 2(8):741\u2013755. https:\/\/doi.org\/10.1158\/2326-6066.CIR-13-0198","journal-title":"Cancer Immunol Res"},{"key":"768_CR9","doi-asserted-by":"crossref","unstructured":"Gardai SJ, Epp A, Law CL (2015) Brentuximab vedotin-mediated immunogenic cell death. Cancer Res 75 (15 Suppl):Abstract 2469","DOI":"10.1158\/1538-7445.AM2015-2469"},{"key":"768_CR10","doi-asserted-by":"crossref","unstructured":"Li F, Zhang X, Emmerton K, Jonas M, Setter J, Arthur B, Okeley N, Lyon R, Benjamin D, Law C-L (2014) Relationship between in vivo antitumor activity of ADC and payload release in preclinical models. Cancer Res 74(19 Suppl):Abstract 3694","DOI":"10.1158\/1538-7445.AM2014-3694"},{"key":"768_CR11","doi-asserted-by":"crossref","unstructured":"Cao A, Heiser R, Law C-L, Gardai SJ (2016) Auristatin-based antibody drug conjugates activate multiple ER stress response pathways resulting in immunogenic cell death and amplified T-cell responses. Cancer Res 76(14 Suppl):Abstract 4914","DOI":"10.1158\/1538-7445.AM2016-4914"},{"issue":"9","key":"768_CR12","doi-asserted-by":"publisher","first-page":"2710","DOI":"10.1158\/0008-5472.CAN-15-1795","volume":"76","author":"F Li","year":"2016","unstructured":"Li F, Emmerton KK, Jonas M, Zhang X, Miyamoto JB, Setter JR, Nicholas ND, Okeley NM, Lyon RP, Benjamin DR, Law CL (2016) Intracellular released payload influences potency and bystander-killing effects of antibody-drug conjugates in preclinical models. Cancer Res 76(9):2710\u20132719. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-1795","journal-title":"Cancer Res"},{"key":"768_CR13","volume-title":"Prescribing information","author":"ADCETRIS","year":"2018","unstructured":"ADCETRIS (2018) Prescribing information. Bothell, Seattle Genetics, Inc"},{"issue":"5","key":"768_CR14","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1002\/(SICI)1096-9896(200004)190:5<613::AID-PATH559>3.0.CO;2-0","volume":"190","author":"H Durkop","year":"2000","unstructured":"Durkop H, Foss HD, Eitelbach F, Anagnostopoulos I, Latza U, Pileri S, Stein H (2000) Expression of the CD30 antigen in non-lymphoid tissues and cells. J Pathol 190(5):613\u2013618. https:\/\/doi.org\/10.1002\/(SICI)1096-9896(200004)190:5<613::AID-PATH559>3.0.CO;2-0","journal-title":"J Pathol"},{"issue":"3","key":"768_CR15","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1097\/PAI.0b013e3181c81d31","volume":"18","author":"SK Lau","year":"2010","unstructured":"Lau SK, Thomas P, Weiss LM (2010) Immunohistochemical evaluation of CON6D\/B5: a new CD30 monoclonal antibody. Appl Immunohistochem Mol Morphol 18(3):273\u2013277. https:\/\/doi.org\/10.1097\/PAI.0b013e3181c81d31","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"3","key":"768_CR16","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1634\/theoncologist.2017-0544","volume":"23","author":"C Albany","year":"2018","unstructured":"Albany C, Einhorn L, Garbo L, Boyd T, Josephson N, Feldman DR (2018) Treatment of CD30-expressing germ cell tumors and sex cord stromal tumors with brentuximab vedotin: identification and report of seven cases. Oncologist 23(3):316\u2013323. https:\/\/doi.org\/10.1634\/theoncologist.2017-0544","journal-title":"Oncologist"},{"issue":"5","key":"768_CR17","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1046\/j.1365-2559.1998.00405.x","volume":"32","author":"MD Garcia-Prats","year":"1998","unstructured":"Garcia-Prats MD, Ballestin C, Sotelo T, Lopez-Encuentra A, Mayordomo JI (1998) A comparative evaluation of immunohistochemical markers for the differential diagnosis of malignant pleural tumours. Histopathology 32(5):462\u2013472","journal-title":"Histopathology"},{"issue":"8","key":"768_CR18","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1002\/1097-0142(19901015)66:8<1732::AID-CNCR2820660815>3.0.CO;2-5","volume":"66","author":"G Mechtersheimer","year":"1990","unstructured":"Mechtersheimer G, Moller P (1990) Expression of Ki-1 antigen (CD30) in mesenchymal tumors. Cancer 66(8):1732\u20131737","journal-title":"Cancer"},{"issue":"9","key":"768_CR19","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1136\/jcp.49.9.762","volume":"49","author":"M Fickers","year":"1996","unstructured":"Fickers M, Theunissen P (1996) Granulocytic sarcoma with expression of CD30. J Clin Pathol 49(9):762\u2013763","journal-title":"J Clin Pathol"},{"key":"768_CR20","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.leukres.2016.02.010","volume":"44","author":"U Borate","year":"2016","unstructured":"Borate U, Mehta A, Reddy V, Tsai M, Josephson N, Schnadig I (2016) Treatment of CD30-positive systemic mastocytosis with brentuximab vedotin. Leuk Res 44:25\u201331. https:\/\/doi.org\/10.1016\/j.leukres.2016.02.010","journal-title":"Leuk Res"},{"issue":"6","key":"768_CR21","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1182\/blood.V89.6.2048","volume":"89","author":"V Gattei","year":"1997","unstructured":"Gattei V, Degan M, Gloghini A, De Iuliis A, Improta S, Rossi FM, Aldinucci D, Perin V, Serraino D, Babare R, Zagonel V, Gruss HJ, Carbone A, Pinto A (1997) CD30 ligand is frequently expressed in human hematopoietic malignancies of myeloid and lymphoid origin. Blood 89(6):2048\u20132059","journal-title":"Blood"},{"issue":"5","key":"768_CR22","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1182\/blood.V74.5.1678.1678","volume":"74","author":"R Schwarting","year":"1989","unstructured":"Schwarting R, Gerdes J, Durkop H, Falini B, Pileri S, Stein H (1989) BER-H2: a new anti-Ki-1 (CD30) monoclonal antibody directed at a formol-resistant epitope. Blood 74(5):1678\u20131689","journal-title":"Blood"},{"issue":"2","key":"768_CR23","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228\u2013247","journal-title":"Eur J Cancer"},{"issue":"4","key":"768_CR24","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1093\/biomet\/26.4.404","volume":"26","author":"CJ Clopper","year":"1934","unstructured":"Clopper CJ, Pearson ES (1934) The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 26(4):404\u2013413. https:\/\/doi.org\/10.1093\/biomet\/26.4.404","journal-title":"Biometrika"},{"key":"768_CR25","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/978-1-4899-3115-3_8","volume-title":"Modelling survival data in medical research","author":"D Collett","year":"1994","unstructured":"Collett D (1994) Interval-censored survival data. In: Collett D (ed) Modelling survival data in medical research, 1st edn. Chapman & Hall, London, pp 237\u2013251","edition":"1"},{"issue":"3","key":"768_CR26","doi-asserted-by":"publisher","DOI":"10.2196\/resprot.7289","volume":"6","author":"B Li","year":"2017","unstructured":"Li B, Eschrich SA, Berglund A, Mitchell M, Fenstermacher D, Danaee H, Dai H, Sullivan D, Trepicchio WL, Dalton WS (2017) Use of the Total Cancer care system to enrich screening for CD30-positive solid tumors for patient enrollment into a brentuximab vedotin clinical trial: a pilot study to evaluate feasibility. JMIR Res Protoc 6(3):e45. https:\/\/doi.org\/10.2196\/resprot.7289","journal-title":"JMIR Res Protoc"},{"issue":"10","key":"768_CR27","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1200\/JCO.2005.04.0543","volume":"24","author":"JJ Lee","year":"2006","unstructured":"Lee JJ, Swain SM (2006) Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol 24(10):1633\u20131642. https:\/\/doi.org\/10.1200\/JCO.2005.04.0543","journal-title":"J Clin Oncol"},{"issue":"6","key":"768_CR28","first-page":"455","volume":"6","author":"SM Swain","year":"2008","unstructured":"Swain SM, Arezzo JC (2008) Neuropathy associated with microtubule inhibitors: diagnosis, incidence, and management. Clin Adv Hematol Oncol 6(6):455\u2013467","journal-title":"Clin Adv Hematol Oncol"},{"issue":"1","key":"768_CR29","doi-asserted-by":"publisher","first-page":"42","DOI":"10.6004\/jnccn.2012.0007","volume":"10","author":"MG Zauderer","year":"2012","unstructured":"Zauderer MG, Krug LM (2012) Novel therapies in phase II and III trials for malignant pleural mesothelioma. J Natl Compr Cancer Network 10(1):42\u201347","journal-title":"J Natl Compr Cancer Network"},{"issue":"3","key":"768_CR30","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.lungcan.2011.08.011","volume":"75","author":"PA Zucali","year":"2012","unstructured":"Zucali PA, Simonelli M, Michetti G, Tiseo M, Ceresoli GL, Collova E, Follador A, Lo Dico M, Moretti A, De Vincenzo F, Lorenzi E, Perrino M, Giordano L, Farina G, Santoro A, Garassino M (2012) Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey. Lung Cancer 75(3):360\u2013367. https:\/\/doi.org\/10.1016\/j.lungcan.2011.08.011","journal-title":"Lung Cancer"},{"issue":"7","key":"768_CR31","doi-asserted-by":"publisher","first-page":"825","DOI":"10.6004\/jnccn.2016.0087","volume":"14","author":"DS Ettinger","year":"2016","unstructured":"Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Dilling T, Dobelbower M, Govindan R, Hennon M, Horn L, Jahan TM, Komaki R, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW Jr, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Sharma N, Swanson SJ, Stevenson J, Tauer K, Yang SC, Gregory K, Hughes M (2016) NCCN guidelines insights: malignant pleural mesothelioma, version 3.2016. J Natl Compr Cancer Network 14(7):825\u2013836","journal-title":"J Natl Compr Cancer Network"},{"issue":"1","key":"768_CR32","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ctrv.2009.09.003","volume":"36","author":"GL Ceresoli","year":"2010","unstructured":"Ceresoli GL, Zucali PA, Gianoncelli L, Lorenzi E, Santoro A (2010) Second-line treatment for malignant pleural mesothelioma. Cancer Treat Rev 36(1):24\u201332. https:\/\/doi.org\/10.1016\/j.ctrv.2009.09.003","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"768_CR33","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1586\/17476348.2015.1083426","volume":"9","author":"O Abdel-Rahman","year":"2015","unstructured":"Abdel-Rahman O, Kelany M (2015) Systemic therapy options for malignant pleural mesothelioma beyond first-line therapy: a systematic review. Expert Rev Respir Med 9(5):533\u2013549. https:\/\/doi.org\/10.1586\/17476348.2015.1083426","journal-title":"Expert Rev Respir Med"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-019-00768-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-019-00768-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-019-00768-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T18:34:39Z","timestamp":1678559679000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-019-00768-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,16]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,8,15]]}},"alternative-id":["768"],"URL":"https:\/\/doi.org\/10.1007\/s10637-019-00768-6","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,16]]},"assertion":[{"value":"21 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The institutions of JS, JJW, LE, AD, GIS, JH, JB, TS, and SIJ received research funding from Seattle Genetics, Inc. NW is an employee of and holds equity interest in Seattle Genetics, Inc. JB has served on an advisory board and Speaker\u2019s Bureau for Seattle Genetics, Inc. TS has served on a Speaker\u2019s Bureau for Seattle Genetics, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author\u2019s disclosure of potential conflicts of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}